Cambrex Corporation (CBM)
(Delayed Data from NYSE)
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.20 USD
+2.73 (6.28%)
Updated May 3, 2019 04:02 PM ET
After-Market: $46.20 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Bayer's sNDA for Stivarga Granted Priority Review in the U.S.
by Zacks Equity Research
Bayer (BAYRY) announced that the FDA has granted priority review designation to its sNDA for Stivarga for the second-line treatment of patients with uHCC.
Bristol-Myers Extends Deal with Five Prime Therapeutics
by Zacks Equity Research
Bristol-Myers (BMY) has exercised its option to extend the research term of the existing collaboration agreement with Five Prime Therapeutics (FPRX).
Ionis (IONS) Stock Up on Positive Type II Diabetes Drug Data
by Zacks Equity Research
Ionis (IONS) announced positive data from a phase II study on IONIS-GCGR for the treatment of patients with type II diabetes.
Clovis Declares Pricing of Upsized Offering of Common Stock
by Zacks Equity Research
Clovis Oncology, Inc. (CLVS) announced the pricing of its underwritten public offering of common stock worth $5 million.
Allergan Natrelle Inspira Breast Implants Approved in the U.S.
by Zacks Equity Research
Allergan plc (AGN) announced that the FDA has approved Natrelle Inspira SoftTouch, a new medium firmness gel, or cohesive, implant option for breast reconstruction, augmentation or revision surgery.
Inotek (ITEK) Down on Poor Phase III Glaucoma Drug Data
by Zacks Equity Research
Shares of Inotek Pharmaceuticals Corporation (ITEK) plunged 71.3% after the company announced that its lead candidate trabodenoson failed to meet the primary endpoint in a phase III trial.
Get Ready To Be Surprised This Earnings Season
by Kevin Matras
Kevin Matras details a good screen to use before and after a company reports this earnings season. Highlighted stocks include MS, PMT, CBM, DTE and CHH.
Sanofi (SNY) Closes Business Exchange Deal with Boehringer
by Zacks Equity Research
Sanofi (SNY) announced the closing of a previously announced deal to exchange its Merial animal health business with Boehringer Ingelheim's consumer healthcare (CHC) segment. The transaction was signed in Jun 2016.
Incyte Treats First Patient in Phase II GVHD Study on Jakafi
by Zacks Equity Research
Incyte Corporation (INCY) announced that the first patient has been treated in the pivotal phase II REACH-1 study assessing its marketed drug Jakafi, in combination with corticosteroids, for the treatment of GVHD.
Corbus Concludes Phase II study of Cystic Fibrosis Candidate
by Zacks Equity Research
Corbus Pharmaceuticals Holdings, Inc. (CRBP), recently announced that it has concluded Phase II trial evaluating pipeline candidate, JBT-101 (resunab), for the treatment of cystic fibrosis (CF).
7 Stocks Near 52 Week-High with More Room to Run
by Zacks Equity Research
Meanwhile, the growing presence of high-valued stocks has made the market overvalued. In such a scenario, it may be naive to invest in value stocks.
ImmunoGen: Phase I Data on Ovarian Cancer Drug Published
by Zacks Equity Research
ImmunoGen, Inc. (IMGN) announced that data from a 46-patient phase I expansion cohort study on its lead pipeline candidate, mirvetuximab soravtansine (IMGN853), were published in the Journal of Clinical Oncology.
Achillion Receives $15M from J&J for HCV Study Enrolment
by Zacks Equity Research
Achillion Pharmaceuticals, Inc. (ACHN) announced that it has received a milestone payment of $15 million from Johnson & Johnson's (JNJ) pharma wing, Janssen for the initiation of patient enrollment in the OMEGA-1 phase IIb global study of JNJ-4178.
Amphastar Stock Down on CRL for Asthma Drug in the U.S.
by Zacks Equity Research
Amphastar Pharmaceuticals, Inc. (AMPH) announced that its subsidiary, Armstrong Pharmaceuticals, Inc., has received a Complete Response Letter (CRL) from the FDA for Primatene Mist (epinephrine inhalation aerosol).
Apricus Launches Vitaros in Lebanon for Erectile Dysfunction
by Zacks Equity Research
Apricus Biosciences, Inc. (APRI) announced that its topical cream, Vitaros for the treatment of erectile dysfunction (ED) has been launched in Lebanon by partner Elis Pharmaceuticals Ltd.
Neothetics (NEOT) Begins Phase II Study on Lead Candidate
by Zacks Equity Research
Neothetics, Inc. (NEOT) announced that it has commenced a phase II proof-of-concept study, LIPO-202-CL-31, on its lead candidate, LIPO-202, for the reduction of submental subcutaneous fat.
Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold
by Zacks Equity Research
Seattle (SGEN) announced that the FDA had placed a clinical hold or partial clinical hold on several early-stage studies on SGN-CD33A for the treatment of AML.
Horizon's Rare Disease Drug Quinsair Launched in Canada
by Zacks Equity Research
Horizon Pharma plc (HZNP) announced the availability of Quinsair (levofloxacin inhalation solution) in Canada for the management of chronic pulmonary infections.
Synergy Reports Positive Top-Line Phase III Data on IBS Drug
by Zacks Equity Research
Synergy Pharmaceuticals announced positive top-line data from a pivotal phase III study evaluating the efficacy and safety of its investigational drug, plecanatide, for the treatment of adult patients suffering from irritable bowel syndrome.
Why MiMedx Group (MDXG) Could Be Positioned for a Slump
by Zacks Equity Research
While MiMedx Group (MDXG) may not be a good pick right now, you can consider other stocks in the same industry.
Ionis Receives $5 Million Milestone from J&J Unit for GI Drug
by Zacks Equity Research
Ionis Pharmaceuticals, Inc. (IONS) announced that it has earned $5 million milestone payment from Janssen Biotech, Inc., a pharmaceutical division of Johnson & Johnson (JNJ).
Celgene's Otezla Gains Positive Recommendation from NICE
by Zacks Equity Research
Celgene Corporation (CELG) announced that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination, recommending the use of its oral phosphodiesterase 4, Otezla.
Cambrex (CBM): Moving Average Crossover Alert
by Zacks Equity Research
Are you a technical investor? If so, it may be time to consider Cambrex Corporation (CBM) for your portfolio.
Teva Settles Foreign Bribery Charges with U.S. Government
by Zacks Equity Research
Teva (TEVA) announced that it has completed negotiations with the U.S. government over violations of the Foreign Corrupt Practices Act.
Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced a clinical trial collaboration with Calithera Biosciences, Inc. (CALA).